This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Walmart is the latest US retail pharmacy giant to announce its intention of disrupting the clinical trials category, with the launch of a new institute that pledges to increase and diversify community access to healthcare research.
Question: What’s the FDA’s approach to unlocking the full promise of real-world evidence? Mr. Gohil said, “When we look at the FDA, since 2016, the industry overall has seen a good amount of adoption. It’s not just the FDA,” he said. I think the pandemic sped that up a bit.
We promptly discussed this need with the FDA and the agency agreed to a proposed amendment of the protocol to accommodate, in a safe manner, the patient access to the EAP.”. Previously he was with Accenture where he led large teams in outsourcing projects across Europe and US for clients in the transportation and retail businesses.
Question: What’s the FDA’s approach to unlocking the full promise of real-world evidence? Mr. Gohil said, “When we look at the FDA, since 2016, the industry overall has seen a good amount of adoption. It’s not just the FDA,” he said. I think the pandemic sped that up a bit.
They've been involved in major clinical studies; they've been working with the FDA as consultants. Then if it that's going to be the case, you're going to sit there for the FDA approval. So not only M&As, the tech, the retail, the pharma that are buying. Because guess what? It's not always going to happen.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content